vs
Embecta Corp.（EMBC）与世纪互联（VNET）财务数据对比。点击上方公司名可切换其他公司
世纪互联的季度营收约是Embecta Corp.的1.4倍（$362.7M vs $261.2M），Embecta Corp.净利率更高（16.9% vs -10.7%，领先27.5%），Embecta Corp.自由现金流更多（$16.6M vs $-193.1M），过去两年世纪互联的营收复合增速更高（17.4% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
VNET Group即世纪互联，是中国领先的第三方中立数据中心服务商，提供机柜托管、云基础设施、混合云部署及网络管理等解决方案，服务覆盖科技、金融、零售等多领域企业客户，为企业数字化运营提供稳定的算力与网络支撑。
EMBC vs VNET — 直观对比
营收规模更大
VNET
是对方的1.4倍
$261.2M
净利率更高
EMBC
高出27.5%
-10.7%
自由现金流更多
EMBC
多$209.7M
$-193.1M
两年增速更快
VNET
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $362.7M |
| 净利润 | $44.1M | $-38.7M |
| 毛利率 | 61.9% | 20.9% |
| 营业利润率 | 31.9% | 0.5% |
| 净利率 | 16.9% | -10.7% |
| 营收同比 | -0.3% | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.74 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCVNET
| Q4 25 | $261.2M | — | ||
| Q3 25 | $264.0M | $362.7M | ||
| Q2 25 | $295.5M | — | ||
| Q1 25 | $259.0M | $309.5M | ||
| Q4 24 | $261.9M | — | ||
| Q3 24 | $286.1M | $302.2M | ||
| Q2 24 | $272.5M | $274.4M | ||
| Q1 24 | $287.2M | $262.9M |
净利润EMBCVNET
| Q4 25 | $44.1M | — | ||
| Q3 25 | $26.4M | $-38.7M | ||
| Q2 25 | $45.5M | — | ||
| Q1 25 | $23.5M | $-2.4M | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $14.6M | $-2.1M | ||
| Q2 24 | $14.7M | $-1.1M | ||
| Q1 24 | $28.9M | $-22.0M |
毛利率EMBCVNET
| Q4 25 | 61.9% | — | ||
| Q3 25 | 60.0% | 20.9% | ||
| Q2 25 | 66.7% | — | ||
| Q1 25 | 63.4% | 25.2% | ||
| Q4 24 | 60.0% | — | ||
| Q3 24 | 60.7% | 23.2% | ||
| Q2 24 | 69.8% | 21.3% | ||
| Q1 24 | 64.6% | 21.6% |
营业利润率EMBCVNET
| Q4 25 | 31.9% | — | ||
| Q3 25 | 21.4% | 0.5% | ||
| Q2 25 | 31.8% | — | ||
| Q1 25 | 24.3% | 0.1% | ||
| Q4 24 | 11.0% | — | ||
| Q3 24 | 9.2% | 24.5% | ||
| Q2 24 | 20.5% | 0.2% | ||
| Q1 24 | 13.6% | 0.2% |
净利率EMBCVNET
| Q4 25 | 16.9% | — | ||
| Q3 25 | 10.0% | -10.7% | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | 9.1% | -0.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.1% | -0.7% | ||
| Q2 24 | 5.4% | -0.4% | ||
| Q1 24 | 10.1% | -8.4% |
每股收益（稀释后）EMBCVNET
| Q4 25 | $0.74 | — | ||
| Q3 25 | $0.44 | — | ||
| Q2 25 | $0.78 | — | ||
| Q1 25 | $0.40 | — | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $0.24 | — | ||
| Q2 24 | $0.25 | — | ||
| Q1 24 | $0.50 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $492.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-613.1M | $890.8M |
| 总资产 | $1.1B | $6.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMBCVNET
| Q4 25 | $201.3M | — | ||
| Q3 25 | $225.5M | $492.1M | ||
| Q2 25 | $230.6M | — | ||
| Q1 25 | $209.3M | $544.3M | ||
| Q4 24 | $210.0M | — | ||
| Q3 24 | $267.5M | $219.5M | ||
| Q2 24 | $275.1M | $247.2M | ||
| Q1 24 | $299.8M | $246.9M |
总债务EMBCVNET
| Q4 25 | — | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.6B | $1.2B | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EMBCVNET
| Q4 25 | $-613.1M | — | ||
| Q3 25 | $-650.6M | $890.8M | ||
| Q2 25 | $-669.6M | — | ||
| Q1 25 | $-736.2M | $927.8M | ||
| Q4 24 | $-768.8M | — | ||
| Q3 24 | $-738.3M | $902.9M | ||
| Q2 24 | $-763.7M | $900.6M | ||
| Q1 24 | $-769.6M | $895.1M |
总资产EMBCVNET
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $6.1B | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.1B | $5.4B | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.3B | $4.3B | ||
| Q2 24 | $1.3B | $4.0B | ||
| Q1 24 | $1.2B | $3.9B |
负债/权益比EMBCVNET
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $113.8M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $-193.1M |
| 自由现金流率自由现金流/营收 | 6.4% | -53.2% |
| 资本支出强度资本支出/营收 | 0.2% | 84.6% |
| 现金转化率经营现金流/净利润 | 0.39× | — |
| 过去12个月自由现金流最近4个季度 | $205.8M | $-589.7M |
8季度趋势，按日历期对齐
经营现金流EMBCVNET
| Q4 25 | $17.2M | — | ||
| Q3 25 | $84.0M | $113.8M | ||
| Q2 25 | $81.2M | — | ||
| Q1 25 | $31.8M | $27.0M | ||
| Q4 24 | $-5.3M | — | ||
| Q3 24 | $26.6M | $108.3M | ||
| Q2 24 | $-2.1M | $55.8M | ||
| Q1 24 | $24.3M | $37.1M |
自由现金流EMBCVNET
| Q4 25 | $16.6M | — | ||
| Q3 25 | $76.7M | $-193.1M | ||
| Q2 25 | $80.8M | — | ||
| Q1 25 | $31.7M | $-220.0M | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | — | $-95.0M | ||
| Q2 24 | $-11.8M | $-81.6M | ||
| Q1 24 | $20.9M | $-102.2M |
自由现金流率EMBCVNET
| Q4 25 | 6.4% | — | ||
| Q3 25 | 29.1% | -53.2% | ||
| Q2 25 | 27.3% | — | ||
| Q1 25 | 12.2% | -71.1% | ||
| Q4 24 | -2.6% | — | ||
| Q3 24 | — | -31.4% | ||
| Q2 24 | -4.3% | -29.8% | ||
| Q1 24 | 7.3% | -38.9% |
资本支出强度EMBCVNET
| Q4 25 | 0.2% | — | ||
| Q3 25 | 2.8% | 84.6% | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.0% | 79.8% | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.0% | 67.3% | ||
| Q2 24 | 3.6% | 50.1% | ||
| Q1 24 | 1.2% | 53.0% |
现金转化率EMBCVNET
| Q4 25 | 0.39× | — | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 1.78× | — | ||
| Q1 25 | 1.35× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | -0.14× | — | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
VNET
暂无分部数据
